BRPI0415299A - uso de polimorfismos genéticos para prognosticar hepatotoxicidade induzida por drogas - Google Patents
uso de polimorfismos genéticos para prognosticar hepatotoxicidade induzida por drogasInfo
- Publication number
- BRPI0415299A BRPI0415299A BRPI0415299-9A BRPI0415299A BRPI0415299A BR PI0415299 A BRPI0415299 A BR PI0415299A BR PI0415299 A BRPI0415299 A BR PI0415299A BR PI0415299 A BRPI0415299 A BR PI0415299A
- Authority
- BR
- Brazil
- Prior art keywords
- hepatotoxicity
- il1a
- genetic polymorphisms
- induced hepatotoxicity
- predict drug
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50897203P | 2003-10-06 | 2003-10-06 | |
| PCT/EP2004/011123 WO2005040415A1 (en) | 2003-10-06 | 2004-10-05 | Use of genetic polymorphisms to predict drug-induced hepatotoxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0415299A true BRPI0415299A (pt) | 2006-12-26 |
Family
ID=34520003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0415299-9A BRPI0415299A (pt) | 2003-10-06 | 2004-10-05 | uso de polimorfismos genéticos para prognosticar hepatotoxicidade induzida por drogas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070248955A1 (enExample) |
| EP (1) | EP1673472B1 (enExample) |
| JP (1) | JP4979382B2 (enExample) |
| CN (1) | CN1882705A (enExample) |
| AT (1) | ATE498021T1 (enExample) |
| AU (1) | AU2004283234B2 (enExample) |
| BR (1) | BRPI0415299A (enExample) |
| CA (1) | CA2540760C (enExample) |
| DE (1) | DE602004031352D1 (enExample) |
| ES (1) | ES2361018T3 (enExample) |
| MX (1) | MXPA06003827A (enExample) |
| PL (1) | PL1673472T3 (enExample) |
| PT (1) | PT1673472E (enExample) |
| WO (1) | WO2005040415A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10262107B1 (en) * | 2013-03-15 | 2019-04-16 | Bao Tran | Pharmacogenetic drug interaction management system |
| CN108949947B (zh) * | 2017-05-25 | 2022-06-28 | 上海市预防医学研究院 | 与抗结核药物性肝损伤发生相关的细胞色素p450基因多态性位点 |
| CN116239665B (zh) * | 2023-03-10 | 2024-08-23 | 山东大学 | Ncf4在制备调控炎症小体激活的制剂中的应用和作为炎症性疾病的治疗靶点中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251598B1 (en) * | 1998-10-30 | 2001-06-26 | Interleukin Genetics, Inc. | Methods for diagnosing sepsis |
| US6214819B1 (en) * | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
| EP1334971A4 (en) * | 2000-10-12 | 2004-05-12 | Takeda Chemical Industries Ltd | BENZIMIDAZOLE COMPOUNDS, METHOD FOR THE PRODUCTION AND USE THEREOF |
| GB0212648D0 (en) * | 2002-05-31 | 2002-07-10 | Immunoclin Lab Ltd | Treatment with cytokines |
-
2004
- 2004-10-05 JP JP2006530097A patent/JP4979382B2/ja not_active Expired - Fee Related
- 2004-10-05 ES ES04765830T patent/ES2361018T3/es not_active Expired - Lifetime
- 2004-10-05 CN CNA2004800344189A patent/CN1882705A/zh active Pending
- 2004-10-05 BR BRPI0415299-9A patent/BRPI0415299A/pt not_active Application Discontinuation
- 2004-10-05 PT PT04765830T patent/PT1673472E/pt unknown
- 2004-10-05 US US10/574,768 patent/US20070248955A1/en not_active Abandoned
- 2004-10-05 DE DE602004031352T patent/DE602004031352D1/de not_active Expired - Lifetime
- 2004-10-05 AU AU2004283234A patent/AU2004283234B2/en not_active Ceased
- 2004-10-05 EP EP04765830A patent/EP1673472B1/en not_active Expired - Lifetime
- 2004-10-05 AT AT04765830T patent/ATE498021T1/de active
- 2004-10-05 WO PCT/EP2004/011123 patent/WO2005040415A1/en not_active Ceased
- 2004-10-05 MX MXPA06003827A patent/MXPA06003827A/es active IP Right Grant
- 2004-10-05 CA CA2540760A patent/CA2540760C/en not_active Expired - Fee Related
- 2004-10-05 PL PL04765830T patent/PL1673472T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070248955A1 (en) | 2007-10-25 |
| CN1882705A (zh) | 2006-12-20 |
| WO2005040415A1 (en) | 2005-05-06 |
| MXPA06003827A (es) | 2006-06-14 |
| EP1673472A1 (en) | 2006-06-28 |
| PL1673472T3 (pl) | 2011-07-29 |
| DE602004031352D1 (de) | 2011-03-24 |
| EP1673472B1 (en) | 2011-02-09 |
| AU2004283234A1 (en) | 2005-05-06 |
| CA2540760A1 (en) | 2005-05-06 |
| CA2540760C (en) | 2013-01-08 |
| JP4979382B2 (ja) | 2012-07-18 |
| PT1673472E (pt) | 2011-05-12 |
| AU2004283234B2 (en) | 2007-08-30 |
| JP2007512231A (ja) | 2007-05-17 |
| ATE498021T1 (de) | 2011-02-15 |
| ES2361018T3 (es) | 2011-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200608961A (en) | Methods and reagents for the treatment of metabolic disorders | |
| MY143215A (en) | Multifocal lenses for pre-presbyopic individuals | |
| CR9223A (es) | 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas,asi como preparaciones farmaceuticas que las contienen | |
| CR10157A (es) | Compuestos químicos | |
| BRPI0607307A2 (pt) | compostos e composições como inibidores de proteìna cinase | |
| MA29369B1 (fr) | Dosage fixe d'anticorps anti-her | |
| ATE449097T1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
| GT200800042A (es) | Metodo de inhibicion de cinasa de tirosina cinasa 3 similar a fms | |
| TR200003525T2 (tr) | Bipolar bozuklukların tedavisi için kombinasyon terapisi | |
| HN2008000360A (es) | Dispersiones amorfas solidas | |
| WO2005082341A3 (en) | NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF | |
| CR10548A (es) | 18-metil-19nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas) asi como preparaciones farmaceuticas que los contienen | |
| GT200300046A (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso | |
| WO2007100777A3 (en) | Methods for the treatment of adhd and related disorders | |
| BR0317284A (pt) | Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno | |
| CL2007002388A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas. | |
| BR0014150A (pt) | Diagnósticos e terapêuticos para osteoporose | |
| MY146805A (en) | 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors | |
| BRPI0513297A (pt) | polipeptìdeo | |
| BRPI0414365A (pt) | composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes | |
| BRPI0415299A (pt) | uso de polimorfismos genéticos para prognosticar hepatotoxicidade induzida por drogas | |
| BR0313588A (pt) | Métodos para o tratamento da demência com base em apo e genótipo | |
| MXPA05008793A (es) | Metodos para la prediccion de posibilidad de suicidio durante el tratamiento. | |
| BRPI0518580A2 (pt) | mÉtodo para melhorar a depuraÇço hepÁtica de substÂncias xenobiàticas em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, e, uso da composiÇço que compreende Ácido lipàico | |
| MX2009004382A (es) | Variaciones geneticas asociadas con tumores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B10A | Cessation: cessation confirmed |
Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DO PROTOCOLO ELETRONICO NO WBRJ 860140010156DE 30/01/2014. |